Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study indicates that finasteride use may lower bladder cancer incidence, while androgen suppression therapy improves recurrence-free survival but not other survival outcomes in bladder cancer patients.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

This review discusses the use of finasteride for treating benign prostatic hyperplasia and highlights its potential for reducing prostate size, symptom control, and lowering the risk of surgery and urinary retention.

This study demonstrated that 12 months of 5 mg daily finasteride treatment reduced prostate volume, dihydrotestosterone, and prostate-specific antigen levels, while improving urinary flow rates and symptom scores in benign prostatic hyperplasia patients.

This review of studies on prostate cancer chemoprevention in Europe reports no robust evidence supporting the effectiveness of chemopreventive agents, though vitamin E and selenium may potentially contribute to prevention efforts.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

This study found that androgen suppression therapy did not significantly reduce bladder cancer incidence overall but suggested finasteride use might lower the risk; recurrence-free survival was improved among AST users.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This analysis concluded that finasteride effectively reduces prostate size and urinary symptoms in benign prostatic hyperplasia, offering a favorable safety profile and versatility as a treatment option.

This review explores prostate cancer risk factors, screening, treatment, and potential roles of selenium and 5-alpha reductase inhibitors in risk reduction but presents no new clinical data.

Finasteride effectively reduces the need for surgery and urinary issues in men with BPH over the long term.

More biopsy cores and MRI before biopsy can improve prostate cancer detection.

This review discusses the impact of medical and surgical treatments for LUTS/BPH on ejaculatory function, highlighting that most treatments negatively affect it, except for some minimally invasive surgical therapies and specific medical therapies.

This study found that men prescribed Finasteride had a lower incidence of bladder cancer compared to those not on the medication, but this protective effect was observed only in Caucasians and Hispanics.

PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

Finasteride may help prevent prostate cancer, but more research is needed.

In this study, researchers found that using a 5-α reductase inhibitor may reduce inflammation-related cytokines associated with T-helper cell 1 and T-helper cell 2 in prostate tissues after surgery, but it did not affect those related to Th17 cells.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

This research highlights that engineered mice lacking the vitamin D receptor show multiple health issues similar to human vitamin D deficiency, underscoring the widespread impacts of the vitamin D endocrine system.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This review covers the potential of SVF and ADSC therapies in regenerative medicine and highlights the challenges of regulation and efficacy, without reporting new clinical results.

This article discusses the side effects of androgen deprivation therapy for nonmetastatic prostate cancer, highlighting the need for clinical trials to systematically study these effects.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.

This review discusses the increasing prevalence of erectile dysfunction in young men and emphasizes the importance of identifying specific causes for effective management, reporting no new clinical results.

This review discusses the potential benefits and risks of 5α-reductase inhibitors in preventing prostate cancer and reports no new results.